文献速递神经肿瘤

墨西哥星形细胞瘤患者MGMT、TP53和AGT的深度DNA测序发现女性基因变异过多及一个预测性生物标志物

Deep DNA sequencing of MGMT, TP53 and AGT in Mexican astrocytoma patients identifies an excess of genetic variants in women and a predictive biomarker.
PubMed 文献 · J Neurooncol · 2022-12-16

研究对48例墨西哥星形细胞瘤患者进行肿瘤样本深度DNA测序,靶向AGT、MGMT和TP53,并检测MGMT启动子甲基化状态,结果与癌症基因组图谱队列比较。发现AGT和MGMT体细胞变异数高于验证队列(10.4% vs <1%,p<0.001),且两队列中仅女性携带AGT变异;MGMT变异或启动子甲基化与更好生存和化疗反应相关,与TP53变异联合与无进展生存相关。

要点

  • 墨西哥星形细胞瘤患者AGT和MGMT体细胞变异频率高于癌症基因组图谱队列(10.4% vs <1%,p<0.001)。
  • 两个队列中仅女性携带AGT变异。
  • MGMT变异或启动子甲基化与更好生存和化疗反应相关,与TP53变异联合与无进展生存相关。

核心结论

  • AGT变异仅见于女性扩展了对星形细胞瘤男女分子差异的认识。
  • 发现队列中AGT和MGMT变异患病率增高提示星形细胞瘤分子景观可能存在人群差异。
  • 作者认为研究结果需进一步研究。

研究设计与样本

  • 研究纳入48例墨西哥星形细胞瘤患者(男性和女性)作为发现队列,对肿瘤样本进行深度DNA测序靶向AGT、MGMT和TP53,并研究MGMT基因启动子甲基化状态。
  • 将发现与包含癌症基因组图谱星形细胞瘤患者数据的验证队列进行比较。

主要发现

  • 发现队列中AGT和MGMT体细胞变异数高于验证队列(10.4% vs <1%,p<0.001)。
  • 两个队列中均观察到仅女性携带AGT变异。
  • MGMT变异或启动子甲基化的存在与更好生存和化疗反应相关。
  • MGMT变异或启动子甲基化与TP53变异联合与无进展生存相关。

局限性

  • 作者指出研究结果需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Astrocytomas are a type of malignant brain tumor with an unfavorable clinical course. The impact of AGT and MGMT somatic variants in the prognosis of astrocytoma is unknown, and it is controversial for TP53. Moreover, there is a lack of knowledge regarding the molecular characteristics of astrocytomas in Mexican patients. METHODS: We studied 48 Mexican patients, men and women, with astrocytoma (discovery cohort). We performed DNA deep sequencing in tumor samples, targeting AGT, MGMT and TP53, and we studied MGMT gene promoter methylation status. Then we compared our findings to a cohort which included data from patients with astrocytoma from The Cancer Genome Atlas (validation cohort). RESULTS: In the discovery cohort, we found a higher number of somatic variants in AGT and MGMT than in the validation cohort (10.4% vs < 1%, p < 0.001), and, in both cohorts, we observed only women carried variants AGT variants. We also found that the presence of either MGMT variant or promoter methylation was associated to better survival and response to chemotherapy, and, in conjunction with TP53 variants, to progression-free survival. CONCLUSIONS: The occurrence of AGT variants only in women expands our knowledge about the molecular differences in astrocytoma between men and women. The increased prevalence of AGT and MGMT variants in the discovery cohort also points towards possible distinctions in the molecular landscape of astrocytoma among populations. Our findings warrant further study.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Carlos-Escalante JA, Mejía-Pérez SI, Soto-Reyes E, et al. Deep DNA sequencing of MGMT, TP53 and AGT in Mexican astrocytoma patients identifies an excess of genetic variants in women and a predictive biomarker. J Neurooncol. 2022. PMID: 36525166. doi:10.1007/s11060-022-04214-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。